1
|
Young ED, Manley SJ, Beadnell TC, Shearin AE, Sasaki K, Zimmerman R, Kauffman E, Vivian CJ, Parasuram A, Iwakuma T, Grandgenett PM, Hollingsworth MA, O'Neil M, Welch DR. Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5. Br J Cancer 2021; 124:166-175. [PMID: 33024269 PMCID: PMC7782545 DOI: 10.1038/s41416-020-01093-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 08/14/2020] [Accepted: 09/03/2020] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Previously, we identified ITIH5 as a suppressor of pancreatic ductal adenocarcinoma (PDAC) metastasis in experimental models. Expression of ITIH5 correlated with decreased cell motility, invasion and metastasis without significant inhibition of primary tumour growth. Here, we tested whether secretion of ITIH5 is required to suppress liver metastasis and sought to understand the role of ITIH5 in human PDAC. METHODS We expressed mutant ITIH5 with deletion of the N-terminal secretion sequence (ITIH5Δs) in highly metastatic human PDAC cell lines. We used a human tissue microarray (TMA) to compare ITIH5 levels in uninvolved pancreas, primary and metastatic PDAC. RESULTS Secretion-deficient ITIH5Δs was sufficient to suppress liver metastasis. Similar to secreted ITIH5, expression of ITIH5Δs was associated with rounded cell morphology, reduced cell motility and reduction of liver metastasis. Expression of ITIH5 is low in both human primary PDAC and matched metastases. CONCLUSIONS Metastasis suppression by ITIH5 may be mediated by an intracellular mechanism. In human PDAC, loss of ITIH5 may be an early event and ITIH5-low PDAC cells in primary tumours may be selected for liver metastasis. Further defining the ITIH5-mediated pathway in PDAC could establish future therapeutic exploitation of this biology and reduce morbidity and mortality associated with PDAC metastasis.
Collapse
Affiliation(s)
- Eric D Young
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Sharon J Manley
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Thomas C Beadnell
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Alexander E Shearin
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Ken Sasaki
- Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan
| | - Rosalyn Zimmerman
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Evan Kauffman
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Carolyn J Vivian
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Aishwarya Parasuram
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Tomoo Iwakuma
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Paul M Grandgenett
- Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Maura O'Neil
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA
| | - Danny R Welch
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
| |
Collapse
|